Business Type:Lab/Research institutions
Product Certification&
Enterprise Certification
Country: China (Mainland)
Business Type:Lab/Research institutions
CAS NO.282526-98-1
99%(1-100)Kilogram
for sale 282526-98-1 282526-98-1 trader with best price Cetilistat
Cetilistat is an inhibitor of pancreatic lipase (IC50s = 5.95 and 54.8 nM for the human and rat enzymes, respectively). It reduces increases in plasma triglyceride levels in an oral fat tolerance test, indicating decreased intestinal fat absorption, in rats when administered at a doses ranging from 3 to 100 mg/kg. Dietary administration of cetilistat (4.9-50.7 mg/kg per day) decreases body weight gain without affecting food intake, as well as reduces increases in plasma triglyceride and leptin levels in a rat model of high-fat diet-induced obesity. It also reduces viral load in the culture supernatant of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC90 = 2.9 µM) and inhibits SARS-CoV-2 replication in a plaque reduction assay (EC50 = 1.13 µM).
Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.
Catalogue Number | C280800 |
Chemical Name | Cetilistat |
Synonyms | 2-(Hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one; ATL 962; |
CAS Number | 282526-98-1 |
Molecular Formula | C??H??NO? |
Appearance | White to Off-White Solid |
Melting Point | 74-76°C |
Molecular Weight | 401.58 |
Storage | Refrigerator |
Solubility | Chloroform (Slightly), Ethyl Acetate (Slightly) |
Category | Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites; |
Applications | A novel pancreatic lipase inhibitor for the treatment of obesity in both diabetic and non-diabetic patients. |